FCFrank Christoph

Frank Christoph

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Frank Christoph has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Testikuläre Keimzelltumoren – Erklärungsmodelle für die hohe Ansprechrate auf Cisplatin-basierte Chemotherapien und neue Therapieoptionen

    by J. Ebbing, F. Christoph, C. Kempkensteffen, S. Weikert, M. Schostak, S. Hinz, M. Lein, K. Miller, M. Schrader

    Dieser Artikel bietet eine Übersicht über die aktuelle Datenlage bei Chemotherapien von Keimzelltumoren. Neben einer kurzen Vorstellung der leitliniengerechten Standardchemotherapie von Keimzelltumoren haben sich die Autoren mit der Frage beschäftigt, warum Keimzelltumoren eine überaus hohe Chemosensibilität im Vergleich zu anderen Tumorentitäten aufweisen. Des Weiteren wird die aktuelle Datenlage zu alternativen Chemotherapien sowie zu molekularen, molekulargenetischen und pharmakogenetischen Therapiekonzepten beleuchtet. Datengrundlage war eine Recherche in MEDLINE der Pubmed-Datenbank. This article offers a review about the current facts of chemotherapy in testicular cancer. Besides a short presentation of the guideline-standard therapy the authors deal with the question as to why testicular cancer shows an extraordinarily high chemosensibility compared to other tumours. Furthermore, the current data on alternative chemotherapies as well as of molecular, molecular-genetic and pharmacogenetic therapeutic concepts are explored. Data were obtained from researches in Medline of the Pubmed database.

  • Expression der pro-apoptotischen Apoptoseinhibitor-(IAP)Antagonisten XAF1, Smac/DIABLO und HtrA2 in Keimzelltumoren des Hodens

    by C. Kempkensteffen, S. Hinz, T. Jäger, S. Weikert, H. Krause, M. Schostak, F. Christoph, R. Strenziok, K. Miller, M. Schrader

    Fragestellung: Eine verminderte Expression der IAP-Antagonisten XAF1, Smac/DIABLO und HtrA2 steht mit der Entwicklung und Progression diverser Tumorentitäten in Verbindung. Ziel dieser Studie war es, die mRNA-Expression dieser pro-apoptotischen Parameter in Keimzelltumoren des Hodens verglichen mit normalem Hodengewebe und eine mögliche Korrelation ihrer Expressionshöhe mit klinischen und pathologischen Charakteristika von Hodentumoren zu untersuchen. Material und Methoden: Die mRNA-Expression von XAF1, Smac/DIABLO und HtrA2 wurde mittels real-time RT-PCR in normalem Hodengewebe (n = 18), TIN-Proben (n = 4), Seminomen (n = 64) und Nichtseminomen (n = 35) quantifiziert. Ergebnisse: Verglichen mit normalen Hodenproben war die Expression von XAF1 in Keimzelltumoren erhöht (p < 0,001), wohingegen die von Smac/DIABLO und HtrA2 erniedrigt war (p < 0,001 und p < 0,001). Für Smac/DIABLO zeigte dabei ein signifikanter Trend in Richtung einer kontinuierlichen Abnahme der Expression von normalem Hodengewebe zu TIN-Proben und Seminomen und letztlich zu Nichtseminomen (p < 0,001). Des Weiteren stieg die Expression von XAF1 und HtrA2 mit Progression des klinischen Tumorstadiums bei Seminompatienten graduell an (p = 0,001 und p = 0,018), wobei die Expression beider Parameter eng korreliert war (Spearman rho Korrelationskoeffizient: 0,674; p < 0,001). Schlussfolgerung: Unsere Ergebnisse deuten auf eine Rolle der verminderten Expression von Smac/DIABLO und HtrA2 bei der Entwicklung und Progression von Keimzelltumoren des Hodens hin, wohingegen die Überexpression von XAF1 in diesen Tumoren möglicherweise zu ihrer außergewöhnlich guten Chemotherapiesensibilität beiträgt. In Anbetracht der zusätzlichen Korrelation der XAF1 und HtrA2 Expression mit dem klinischen Tumorstadium von Seminompatienten erscheint es sinnvoll, alle 3 IAP-Antagonisten als mögliche molekulare Parameter für die Vorhersage des Therapieansprechens und der Prognose von Keimzelltumorpatienten weiter zu evaluieren. Purpose: Down-regulation of the IAP antagonistis XAF1, Smac/DIABLO and HtrA2, has been related to the onset and progression of various malignancies. We examined the mRNA-expression of these pro-apoptotic parameters in testicular germ cell tumors (TGCT) and normal testicular tissue and correlated their expression levels to clinicopathological tumour features.Material and Methods: Real-time RT-PCR was used to quantify the mRNA-expression of XAF1, Smac/DIABLO and HtrA2 in normal testicular tissue (n = 18), carcinoma in situ (n = 4), seminomas (n = 64), and non-seminomatous germ cell tumors (n = 35). Results: Compared to normal testicular tissue, the expression levels of XAF1 were increased in TGCT (p < 0.001), whereas those of Smac/DIABLO and HtrA2 were decreased (p < 0.001 and p < 0.001). Smac/DIABLO expression levels showed a significant trend towards a gradual decrease from normal testicular tissue to CIS and seminomas and finally to NSGCT (p < 0.001). Moreover, XAF1 and HtrA2 expression levels gradually increased with progression of clinical tumour stage in seminoma patients (p = 0.001 and p = 0.018), their expression levels being strongly intercorrelated (Spearman rho correlation coefficient: 0.674; p < 0.001). Conclusion: These data suggest that a down-regulation of Smac/DIABLO and HtrA2 is implicated in the development and progression of TGCT, whereas overexpression of XAF1 in TGCT might contribute to their extraordinary sensitivity to chemotherapy. Regarding the additional correlation of XAF1 and HtrA2 expression with clinical tumour stage in seminoma patients, it appears reasonable to further evaluate these three IAP antagonists as molecular parameters for the prediction of treatment response and prognosis of TGCT patients.


  • Comparative Promoter Methylation Analysis of p53 Target Genes in Urogenital Cancers

    by Frank Christoph, Stefan Hinz, Steffen Weikert, Carsten Kempkensteffen, Martin Schostak, Kurt Miller, Mark Schrader

    Introduction: The methylation status of selected new p53 target genes in bladder, kidney and testicular cancer was investigated to find similarities in methylation frequency and individual levels of methylation with regard to the histopathological classification and biological behavior. Material and Methods: The patients’ samples were evaluated using real-time methylation-specific PCR (MSP) investigating the methylation status of APAF-1, CASP-8, DAPK-1 and IGFBP-3. Included were 103 patients with bladder cancer, 85 patients with kidney cancer and 42 patients with testicular cancer in non-advanced and advanced tumor stages. Non-cancerous tissue from 49 patients was used as control. Results: Methylation frequency was highest for APAF-1 (88–100%) and DAPK-1 (17–86%) through all the different tumor types. Highest APAF-1 and DAPK-1 levels of methylation were found in the advanced tumor groups. In normal tissue, methylation frequency and methylation levels were significantly lower. APAF-1 methylation was also frequent in normal testicular tissue but to lower methylation levels as in cancerous tissue. APAF-1 and IGFBP-3 methylation levels were significantly higher in recurrent superficial and muscle-invasive bladder tumors. Methylation levels of APAF-1 also correlated with higher risk for recurrent metastatic disease in non-advanced tumors of the kidney. Conclusions: The methylation profile observed demonstrates a substantial role of the APAF-1 gene in tumorigenesis. The different methylation pattern in testicular cancer might represent a different methylotype of this cancer. The extent of promoter methylation may be a promising target for application as a tumor marker in urogenital cancer disease.


  • mRNA Expression Profiles of MethylatedAPAF-1andDAPK-1Tumor Suppressor Genes Uncover Clear Cell Renal Cell Carcinomas With Aggressive Phenotype

    by F. Christoph, S. Hinz, C. Kempkensteffen, M. Schostak, M. Schrader, K. Miller

    We determined the relation between promoter methylation and mRNA expression of the p53 target genes APAF-1 and DAPK-1 in 55 consecutive tumor and corresponding normal tissue samples. Tissue was taken from nonmetastatic clear cell renal cell carcinoma at a median followup of 75 months. Quantitative methylation specific real-time polymerase chain reaction and quantitative real-time reverse transcriptase-polymerase chain reaction were used. The mRNA expression levels of APAF-1 and DAPK-1 were significantly higher in tumor vs nontumor tissue from the same kidney (p = 0.003 and 0.0001, respectively). Expression levels of the 2 genes did not correlate with tumor stage but they were significantly lower in high grade (G3) tumors (p = 0.018 and 0.05, respectively). In patients with positive lymph node staging mRNA expression of APAF-1 and DAPK-1 was significantly lower. On matched pair analysis of tumor tissue the methylation level of the APAF-1 gene correlated inversely with the mRNA expression level (p = 0.02). In tumor and normal kidney tissue from patients with lesions 4 cm or greater mRNA expression levels of DAPK-1 were significantly lower in those who later had metastatic disease (p = 0.04 and 0.02, respectively). These data demonstrate decreased tumor suppressor gene expression in more aggressive subtypes of clear cell renal cell carcinoma. The lower mRNA level of the DAPK-1 gene in tumor and normal tissue from patients with an unfavorable clinical outcome suggests the organ specific loss of tumor suppressor gene expression, predisposing to metastatic tumor disease and shorter overall survival.


  • Frequent epigenetic inactivation of p53 target genes in seminomatous and nonseminomatous germ cell tumors

    by F. Christoph, C. Kempkensteffen, S. Weikert, H. Krause, M. Schostak, K. Miller, M. Schrader


  • A gene expression profile of tumor suppressor genes commonly methylated in bladder cancer

    by Frank Christoph, Stefan Hinz, Carsten Kempkensteffen, Steffen Weikert, Hans Krause, Martin Schostak, Mark Schrader, Kurt Miller

    The functional relationship between promoter hypermethylation and gene inactivation has been demonstrated for few genes only. We examined the promoter methylation status of two important tumor suppressor genes APAF-1 and DAPK-1 in bladder cancer as well as the mRNA expression pattern of these two genes for possible correlation between promoter hypermethylation and transcriptional repression.


  • Open Access

    Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer

    by F Christoph, C Kempkensteffen, S Weikert, J Köllermann, H Krause, K Miller, M Schostak, M Schrader

    To examine the significance of the methylation level of the p53 target and tumour suppressor genes apoptotic protease activating factor-1 (APAF-1) and death-associated protein kinase-1 (DAPK-1) in 80 microdissected tumour samples from transitional cell carcinoma (TCC) of the bladder and 80 tumour samples from clear-cell renal cell carcinoma (RCC) as well as from non-tumourous bladder and kidney tissue. Growth-inhibitory effects of the demethylating agents 5-Aza-2′-deoxycytidine (5-Aza-CdR) and zebularine were investigated in TCC and RCC cell lines. The methylation frequency of APAF-1 (DAPK-1) was 100% (77%) in TCC and 100% (33%) in RCC. The methylation levels of APAF-1 could differentiate between the individual tumour stages in TCC as well as in RCC. The APAF-1 methylation levels in RCC were significantly higher in tumours larger than 4 cm and in high-grade tumours. The methylation frequencies in normal tissue for APAF-1 (DAPK-1) were 11% (8%) in bladder tissue and 9% (5%) in kidney tissue. The growth-inhibitory effect of the demethylating agents in TCC (RT4, T24) and RCC (A498, ClearCa-5) cell lines resulted in a 17–132% prolongation of the doubling time (DT). In RCC cell lines, zebularine was superior to 5-Aza-CdR in achieving a DT prolongation. Quantitative real time RT-PCR detected a re-expression of mRNA transcripts of APAF-1 or DAPK-1. In conclusion, demethylating agents effectively retard growth of TCC and RCC cell lines. Methylation level analysis of specific genes has the potential for further tumour characterisation in TCC and RCC.


  • Open Access

    Promoter Hypermethylation Profile of Kidney Cancer with New Proapoptotic p53 Target Genes and Clinical Implications

    by Frank Christoph, Steffen Weikert, Carsten Kempkensteffen, Hans Krause, Martin Schostak, Jens KölLermann, Kurt Miller, Mark Schrader

    Purpose: Risk stratification of renal cell carcinoma is based on the histopathologic classification. Promoter hypermethylation as a mechanism of gene inactivation in renal cell carcinoma has been shown for only a small number of genes. We examined the usefulness of quantitative methylation analysis with a new set of p53 target genes for determining the clinical outcome and aggressiveness of the tumor disease. Experimental Design: The genes selected were APAF-1, CASPASE-8, DAPK-1, IGFBP-3, and PML. The tissue samples analyzed were taken from tumor specimens obtained from 90 consecutive patients with clear cell renal carcinoma and from 20 normal kidney specimens. Quantitative methylation analysis of CpG sites in the promoter region was done by methylation-specific real-time PCR and the normalized index of methylation (NIM) was determined for each sample. Results: Hypermethylation of the promoter region was common for APAF-1 (97%) and DAPK-1 (41%) but not for IGFBP-3 (3%), PML (3%), or CASP-8 (0%). The tumor patients had a median follow-up of 55 months. A correlation was found between the methylation level of APAF-1 and tumor size and nodal status, but not for tumor stage, grade, and age of patient. Kaplan-Meier analysis was able to identify patients with a higher risk of recurrence and tumor-related death by using APAF-1 (≥56% NIM) and DAPK-1 (≥10% NIM) methylation levels. In multivariate analysis, APAF-1 and DAPK-1 methylation levels were independent prognostic markers for metastatic disease and death from renal cell carcinoma. Conclusions: Our findings indicate that promoter hypermethylation of APAF-1 and DAPK-1 is a marker of aggressive renal cell carcinoma and provides independent prognostic information on disease outcome.


  • Open Access

    Regularly methylated novel pro‐apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder

    by Frank Christoph, Steffen Weikert, Carsten Kempkensteffen, Hans Krause, Martin Schostak, Kurt Miller, Mark Schrader

    Epigenetic silencing of tumor suppressor genes by promoter hypermethylation has been shown for a variety of genes in bladder cancer. Various p53 target genes have been investigated, but only few demonstrated promoter hypermethylation when semiquantitative detection methods were applied. To address to the question whether promoter methylation of novel p53 effector genes is a common event in transitional cell carcinoma of the bladder, we selected the p53 target genes apoptotic protein‐activating factor (APAF‐1), Caspase 8 (CASP‐8), death‐associated protein kinase, (DAPK‐1) and insulin‐like growth‐factor‐binding protein‐3 (IGFBP‐3), performing quantitative methylation‐specific real‐time PCR. The individual level of methylation (normalized index of methylation) was correlated with clinicopathological features as well as the biological behavior of the superficial and muscleinvasive tumors. Tissue was obtained from 110 tumor patients and 20 patients without urological malignancy. The median follow‐up of the tumor patients was 52 months. Hypermethylation of the promoter region in tumor specimens was common for APAF‐1 (100%), DAPK‐1 (74%) and IGFBP‐3 (66%), but not for CASP‐8 (3.6%). It was seen less frequently and with undetectable or low methylation levels in the normal urothelium group. The APAF‐1 methylation levels significantly correlated with tumor stage and tumor grade. The APAF‐1 and IGFBP‐3 methylation levels were able to separate tumors with higher recurrence risk from low‐risk tumors in nonmuscleinvasive and muscleinvasive tumors. In multivariate analysis, APAF‐1 and IGFBP‐3 methylation levels were independent prognostic markers for recurrence in superficial bladder tumors. This study provides new insights into the role of promoter methylation of selected p53 target genes. The extent of promoter methylation of specific genes offers additional prognostical information and is associated with the outcome in patients with nonmuscleinvasive and muscleinvasive bladder cancer.


  • Open Access

    Quantitative real-time RT-PCR of CD24 mRNA in the detection of prostate cancer

    by M Schostak, H Krause, K Miller, M Schrader, S Weikert, F Christoph, C Kempkensteffen, J Kollermann

    Background: Gene expression profiling has recently shown that the mRNA for CD24 is overexpressed in prostate carcinomas (Pca) compared to benign or normal prostate epithelial tissues. Immunohistochemical studies have reported the usefulness of anti-CD24 for detecting prostate cancer over the full range of prostate specimens encountered in surgical pathology, e.g. needle biopsies, transurethral resection of prostate chips, or prostatectomies. It is a small mucin-like cell surface protein and thus promises to become at least a standard adjunctive stain for atypical prostate biopsies. We tested the usefulness of real-time RT-PCR for specific and sensitive detection of CD24 transcripts as a supplementary measure for discriminating between malignant and benign lesions in prostatic tissues.Methods: Total RNA was isolated from snap-frozen chips in 55 cases of benign prostatic hyperplasia (BPH) and from frozen sections in 59 prostatectomy cases. The latter contain at least 50% malignant epithelia. Relative quantification of CD24 transcripts was performed on the LightCycler instrument using hybridization probes for detection and porphobilinogen deaminase transcripts (PBGD) for normalization.Results: Normalized CD24 transcript levels showed an average 2.69-fold increase in 59 Pca-cases (mean 0.21) when compared to 55 cases of BPH (mean 0.08). This difference was highly significant (p < 0.0001). The method has a moderate specificity (47.3%) but a high sensitivity (86.4%) if the cutoff is set at 0.0498. CD24 expression levels among Pca cases were not statistically associated with the tumor and lymph-node stage, the grading (WHO), the surgical margins, or the Gleason score.Conclusion: The present study demonstrates the feasibility of quantitative CD24 RNA transcript detection in prostatic tissues even without previous laser microdissection.